Across 3 studies, all reported beneficial effects of Bacopa monnieri on attention span, with effect sizes ranging from small to moderate. The most robust evidence comes from a 2024 triple-blinded RCT (62 patients with mild cognitive impairment) showing significant improvements at 60 days with 160 mg/day. Effects typically observed at 4-8 weeks.
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Two of the three studies are reviews, and only one RCT with a modest sample size (n=62) provides controlled dose and duration data.
Bacopa monnieri consistently improved inattention, hyperactivity, and memory
While in the field of attention at the end of the first month (P = 0.033) and the end of the second month (P = 0.004), it was significant difference between the study groups.
BM can reduce Nuclear Factor-κB phosphorylation, improve emotional function, cognitive functions, anhedonia, hyperactivity, sleep routine, depression, attention deficit, learning problems, memory retention, impulsivity, and psychiatric problems.